However, there are no reports to date of a comprehensive screening approach to investigate the mechanism of resistance to PARP inhibition, especially in the context of ovarian cancer where maintenance PARP inhibitor therapy is of clinical benefit. The gene discussed is PARP1; the disease is ovarian carcinoma.